The influenza virus is the causative agent of the flu, a contagious respiratory illness that causes morbidity, loss of productivity, and, in some instances, death. Although the seasonal flu is typically only life threatening to high‐risk groups, exceptionally virulent forms of the virus that emerge during pandemics, can even threaten strong and otherwise healthy individuals. A strong arsenal of antiviral drugs is essential during a pandemic, but drug resistance threatens our preparedness. A key target for antivirals is neuraminidase, an enzyme that cleaves glycosidic bonds between sialic acid residues on cell surface glycoproteins so that the virus can infect or escape from host cells to repeat the cycle of infection. The enzyme exists as a homo‐tetramer with calcium ions stabilizing the protein structure. Antiviral medications, including Oseltamivir and Zanamivir, inhibit neuraminidase activity but resistance to Oseltamivir is most prevalent. The challenges posed by the rapid evolution of drug resistance have led Dr. Schiffer and her colleagues to develop more innovative ways, based on structural analyses to formulate drugs that are immune to resistance. We chose to focus on resistance of the His274Tyr neuraminidase mutant to the drug Oseltamivir using the crystal structure solved by Collins and colleagues that demonstrates that this resistance is due to a shift in the position of Glu276 into the hydrophobic pocket of the active site. Using the software application, Jmol, we designed physical models based on the overlaid crystal structures of the wild type and the His274Tyr mutant to visualize the shift in Glu276 and its impact on binding of each of three potential ligands: Oseltamivir, Zanamivir, and Sialic Acid. In addition, the catalytic residues Tyr406 and Glu277 were displayed to visualize the lack of impact on catalytic cleavage of the natural substrate, but continued inhibition by Zanamivir. By designing a physical model of Neuraminidase to emphasize the dimensional and catalytic residues, a better understanding of the protein’s function and potential inhibition by drugs can be obtained and may lead to a more effective way to design drugs in the future.Support or Funding InformationSupport for the CREST Project is through NSF‐IUSE #1725940.